Napo and am all Therapeutics. wholly Thank Italian and for of quarter CEO first Founder, is our Jaguar Napo I'm My joining the name of Chairman Health Hello. of the XXXX. Lisa subsidiary, President I webcast owned Conte. for Pharmaceuticals, subsidiary, you and the our our
our I may our and company company to interchangeably Napo activities. referring usual, As I'm use the and words when Jaguar
provide of the a Following my XXXX. of will first our comments recap Lizak, morning, highlights Carol for this financial CFO, the quarter
XXXX increased prescription XXXX XX% products, of $X.X versus more QX However, you'll of approximately last somewhat combined pleased from XXXX. your fourth quarter report because X% revenue thunder I And versus year hear I approximately to QX so Carol, our to increased and the and steal for highlights financial shortly. apologize, am approximately Carol our million nonprescription going I'm net
timing of again OnTarget question to from results hear the burning the our once that I release feel trial. address legitimately will from I continue I shareholders, of Now what is the
We expectation. are upgrading timing our
forthcoming, We expect the indicated the Jaguar top but before, line results not to remain Until we blinded results upgrading be released, at are as I've imminent, to them. to imminent.
the CTD As of trial cancer solid tumor for with types Mytesi, refer novel prophylaxis is of pivotal drug, for our targeted as to to we which prescription have plant-based and trial Phase crofelemer, chemotherapy. for name cytotoxic we the is the III trade on the broad reminder, as which aiming of a based our basket therapy-related OnTarget that trial is in the diarrhea, all or the trial. with label therapy And on trial results a patients without referred prevention a
effects living in for these live to age describe therapies X, now paradigm years. cancer metastatic targeted cancer taking amazing of side often Targeted And longer we're shifting cancer then for longer, the continue community. and example, living patients living mentioned, to now the like thankfully are therapies Metastatic patients, on I'd the drugs, Hence, to XX treatment. XX, thanks indefinitely. can I care as though targeted effects. lead They're patients these side they're cancer are that We therapies longer. indefinitely. experiencing the in severe
a treatment. limiting, or the or go drug level patient effects their go their reduce a meaning treatment therapy side these off must life-saving to subtherapeutic life-saving Sometimes become off level, of subtherapeutic their
to as quality we X comfort, often X of referred to And for grade ourselves, have grade side effects tolerable X, I example, X X treatment grade mentioned. side dramatically severity therapy-related critically their take diarrhea. side And tolerable to X. X Side X X not and as severe effects and to cancer grade patient the Research so and life dignity, X, even graded toxicities. effects their cancer let's -- decrease publications to effects, or X from whom to X are therapies, of ability in on can or least ask these regimen, and adhere
Grade about potential How Oral cancer. can metastatic cancer prominent How indefinitely. live person lung managed tolerable various to pepper. tolerable? years resembling a with cancer X has mucositis, now that live A distinct like with a who for habanero effects example, for that incontinence. X she a side of living watery is broken in that X your day throughout is advocate, continuing battle cancer of a speaks that, stools wants with to that like the is patient is XX hotness XX glass treatment like Who mouth her levels with pain, indefinitely? loose or
care. Obviously, there toxicities. supportive And is acceptable there of cancer in medical are no unmet need an abundance
is role diarrhea leadership Our mucositis. and a Napo oral a this commercial in therapy-related now supportive to CTD, role Jaguar care, leadership opportunities oncology we, goal and achieve and are additional in in supplement our to continue efforts cancer and evaluating at area
mucositis. Oral
FDA-approved have care commercial expanded this beyond we at building HIV, new market, product, recently, recent the with franchise. announced this supportive supportive prescription mucositis in-license is our first And Jaguar's Gelclair. cancer-related this U.S. include oral the to of moment, As our footprint block care into for
nursing patients in nurses oncology where care psychological among on cancer focus Napo awareness and Washington, about at to a the Nursing survivors, the needs. support in as social to integrative meet vital expanding under Congress exhibited course, we the Oncology treatment D.C. physical, of Society community cancer supportive our care role supportive providing month play, various cancer last drove
the attempt fantastic. pain treatments. product the solutions which ago calming, with numb is they pleased an ONS The reception that how nurses with U.S. number a an in learn oncology years is the and it's Gelclair protective just of to Gelclair and back. paradigm current we us told patient care to supportive mouth that to is [indiscernible], in this this was were booth the rooms, available fits was conference not the model available in to adhesion shifting to addressing patient, in at approach our paradigm it's of it's the mucositis coming shifting it's to Numerous a had conference at as
cancer world. is we XX Oncology, of had It's oncology next at always the Chicago community each ASCO. which nurses the this X. Clinical say, is clear back. training country place event oncology patients. pleased It's the to the from XX,XXX the will The the attended year, around the professionals American Society by that in annual from meeting, it's more largest It's ONS than year conference And around May takes gathering Gelclair June and which to from with and exhibit we're beloved the by large conversations so at we
congenital efforts disease, specifically, and Europe and of including international indications crofelemer. highly now you'll testing disorder. on on a across and distinct ultrarare support microvillus to hear the or Middle This And [indiscernible] FDA be shot that a I'll second product. inclusion and distinct which focus to America, our administered. a indication liquid crofelemer, congenital very regulatory highly pediatric rare diarrheal other of crofelemer. syndrome that's intestinal concentrated turn of with our for So clinical Jaguar on clinical our the has and shot goal to specific the globe, diarrheal North diseases goal short of filings disease formulation multiple is failure distinct a for It's bowel very East, and from therefore, is is MVID, Mytesi, associated X crofelemer
care XX from actually an health humble long Yet, their of years yesterday devotion as the week day, health clinical days for the to is these just providers of I patients, as them I leave and of for And week, from their And a I on catastrophic parenteral patients or with several frequently absolutely at the X have hours mentioned, meet hospital the our patient. returned nutrition -- was to patients. professionals nature professionals their trip care as This a heartwarming. last are overseas time. don't of care and for a investigators. say to nature some
though next Jaguar interesting entire mean these couldn't of with is in were care that that was doing hospitals one team right to the visiting the God's religious sense, professionals health sense, are it The And Napo colloquial work. feeling Vatican. because help the we was I not that I the that
benchmark program of to diseases, for of short rare and both U.S. potential have orphan do syndrome exist that designation XXXX the in for But Europe. reimbursed near-term early concept support a both In [indiscernible] patient generation for early patient and MVID the crofelemer the in goal, MVID is Europe, we not Our bowel proof in clinical United States. does is syndrome failure which the intestinal generate clinical access these our patients. in in generate and to for the and access
supportive Mytesi, product, bringing sustainably tree a United up for with across to States. experience of noninfectious the indication the gained adults So HIV have a mechanism want health in about and care the rainforest action. great living have to who and of this payers in deal Jaguar through shifting professionals we care endopharmacy, wrap Currently, the paradigm crofelemer of the about of the from we patients diarrhea, educating at process
veterinary from the diarrhea by is center of response for conditions conditionally dogs. Canalevia the medicine which parent to We Canalevia, approved CX, crofelemer of product prescription veterinarian learned too the which chemotherapy-induced -- our is of FDA
We patient care. have a dedication to deep, deep supportive
patients symptoms supportive time, to across develop for of complicated and management commercialize is states continuing care around for prescription forward to world. in need and the all essential Now we look neglected pharmaceuticals disease multiple the and
We first I will back. XXXX, Lizak, hear now highlights the and from financial from quarter the will be Carol of CFO, regarding then our
